Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JHG
|
|||
| Former ID |
DIB011865
|
|||
| Drug Name |
ChimeriVax-Dengue
|
|||
| Synonyms |
CYD dengue vaccine; ChimeriVax-DEN; ChimeriVax-DEN2; Chimerivax-DEN1-4; Dengue vaccine, Peptide Therapeutics/Aventis Pasteur; ChimeriVax (dengue), Acambis/Aventis Pasteur; ChimeriVax (dengue), Peptide Therapeutics/Aventis Pasteur; Dengue vaccine (recombinant chimeric), Acambis/Aventis Pasteur; ChimeriVax (dengue), Acambis/sanofi-aventis; Dengue vaccine (recombinant chimeric), Acambis/sanofi-aventis
Click to Show/Hide
|
|||
| Indication | Dengue fever [ICD-11: 1D2Z; ICD-10: A97, A97.9; ICD-9: 61] | Phase 2 | [1] | |
| Company |
St Louis University
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00730288) Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.